Lycera
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Dauphin, Pennsylvania, 17018, United Sta...Phone Number
(734) 233-3060Website
www.lycera.comRevenue
$6.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Lycera
Lycera is a biopharmaceutical company advancing novel treatments for cancer and autoimmune diseases based on a proprietary portfolio of small molecules designed primarily to either suppress or activate the immune response. The Company's world-class expertise in distinct, yet complementary, areas of research - immune metabolism, cell signaling and immune cell differentiation - has generated four wholly owned programs, including a lead product candidate to treat inflammatory bowel disease (LYC-30937) expected to enter clinical testing in the first half of 2015. In addition, Lycera has established two collaborations with partner Merck to discover, develop and commercialize small molecule therapies for autoimmune disorders. The Lycera leadership team possesses deep experience from drug discovery and development through commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide. Lead investors in Lycera include InterWest PartneRead more
Lycera Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lycera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Lycera is spiking on competitors!
Check if Lycera has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Lycera has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Lycera launches new products
Earning: See what the market has to say on Lycera recently announced quarterly report
Click to see if Lycera had a recent Job posting/layoffs
Lycera, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Lycera
Recommended Actions
Reach out to Masked Content who joined Lycera as Masked Content
Find 3 more new buyers
Compare Similar Companies to Lycera
Compare insights from companies similar to Lycera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lycera is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lycera is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lycera.
Lycera financials insights
Gather financial insights about Lycera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Series A
$36M
2012
Private Equity
$21M
2013
Debt
$5M
2014
Debt
$4M
2015
Series B
$29.9M
2020
Debt
$350K
Lycera Tech Stack
A closer look at the technologies used by Lycera
Lycera News & Media
Lycera Announces Initiation of Phase 1b Study of Novel Immuno-Oncology Candidate LYC-55716 in Combination with Pembrolizumab
NEW YORK and ANN ARBOR, Mich., Jan. 4, 2018 /PRNewswire/ -- Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the initiation of a Phase 1b clinical trial of the company's novel immuno-oncology therapeutic...Lycera Presents Tumor Selection Rationale for Phase 2a Study at Society for Immunotherapy of Cancer's (SITC) 2017 Annual Meeting for RORgamma Agonist, LYC-55716
NEW YORK and ANN ARBOR, Mich., Nov. 7, 2017 /PRNewswire/ -- Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the presentation of scientific data supporting the selection of tumor types for Lycera's ongoing Phase 1...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lycera
Sign Up For FreeTo access detailed company insights
Lycera is a biopharmaceutical company advancing novel treatments for cancer and autoimmune diseases based on a proprietary portfolio of small molecules designed primarily to either suppress or activate the immune response. The Company's world-class expertise in distinct, yet complementary, areas of research - immune metabolism, cell signaling and i... Read More
